5,565 Elevance Health, Inc. $ELV Shares Sold by TD Waterhouse Canada Inc.

TD Waterhouse Canada Inc. lowered its position in Elevance Health, Inc. (NYSE:ELV – Free Report) by 24.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,033 shares of the company’s stock after selling 5,565 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in Elevance Health were worth $6,504,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in ELV. Aspiriant LLC acquired a new stake in shares of Elevance Health during the third quarter valued at about $236,000. Goelzer Investment Management Inc. boosted its holdings in Elevance Health by 2.4% in the third quarter. Goelzer Investment Management Inc. now owns 4,995 shares of the company’s stock valued at $1,942,000 after purchasing an additional 118 shares during the last quarter. Cantor Fitzgerald Investment Advisors L.P. boosted its holdings in Elevance Health by 1.8% in the third quarter. Cantor Fitzgerald Investment Advisors L.P. now owns 4,030 shares of the company’s stock valued at $1,567,000 after purchasing an additional 70 shares during the last quarter. Activest Wealth Management boosted its holdings in Elevance Health by 146.2% in the third quarter. Activest Wealth Management now owns 64 shares of the company’s stock valued at $25,000 after purchasing an additional 38 shares during the last quarter. Finally, Triasima Portfolio Management inc. acquired a new stake in Elevance Health during the 3rd quarter valued at approximately $436,000. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Stock Performance

Shares of NYSE ELV opened at $430.06 on Tuesday. Elevance Health, Inc. has a 12-month low of $274.84 and a 12-month high of $436.24. The company has a market cap of $93.27 billion, a PE ratio of 14.57, a P/E/G ratio of 2.23 and a beta of 0.70. The stock has a 50 day simple moving average of $404.84 and a 200-day simple moving average of $387.58. The company has a current ratio of 1.52, a quick ratio of 1.52 and a debt-to-equity ratio of 0.68.

Wall Street Analyst Weigh In

Several research firms have issued reports on ELV. Royal Bank Of Canada dropped their price objective on Elevance Health from $439.00 to $424.00 and set a “sector perform” rating on the stock in a report on Thursday, July 16th. Sanford C. Bernstein set a $488.00 target price on Elevance Health in a research report on Thursday, July 16th. Barclays increased their target price on Elevance Health from $457.00 to $469.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Wall Street Zen downgraded shares of Elevance Health from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Finally, Cantor Fitzgerald raised their price target on shares of Elevance Health from $400.00 to $450.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 7th. Fifteen investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Elevance Health has a consensus rating of “Moderate Buy” and an average target price of $441.71.

Check Out Our Latest Research Report on ELV

Elevance Health Company Profile

(Free Report)

Elevance Health, Inc (NYSE: ELV) is a diversified health benefits company that provides health insurance and related services in the United States. Its offerings serve employers, individuals and families, as well as members of government-sponsored programs, including Medicare and Medicaid. The company provides medical, pharmacy, behavioral health and other benefits through a range of health plans and specialty products.

Elevance Health operates its health benefits businesses through a portfolio that includes Blue Cross and Blue Shield-affiliated plans and other insurance offerings.

See Also

• Five stocks we like better than Elevance Health
• Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves
• The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway
• Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants
• Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?

Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report).